The rule
basically states that a company's Phase III trial will be
a failure if the trial is cancer related and the company has a market
capitalization of under $300 million with 120 days or less to go before the data
release. This rule has been researched for over 10 years and is 23 for 23 so
far, basically a 100% success rate for investors who follow this rule.
Additionally, companies that have a pending Phase III but have a market
capitalization of at least $1 billion have a success rate of 78%.
No comments:
Post a Comment